Total assets grew to $157.3M and equity to $86.9M in 2026Q3 with a current ratio of 1.79 and debt-to-equity of 0.28, though debt-to-equity has swung between 0.14 and 1.28 over the period, warranting monitoring.
Eton Pharmaceuticals, Inc. (ETON) balance sheet — 9-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 |
|---|
| Total Current Assets | 96.78M | 60.58M | 41.02M | 26.84M | 20M | 23.6M | 24.7M | 15.01M | 27.5M | 13.29M |
| Cash & Short-Term Investments | 55.63M | 25.94M | 14.94M | 21.39M | 16.3M | 14.41M | 21.3M | 12.07M | 26.73M | 13.16M |
| Cash Only | 55.63M | 25.94M | 14.94M | 21.39M | 16.3M | 14.41M | 21.3M | 12.07M | 26.73M | 13.16M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 26.43M | 11.76M | 5.36M | 3.41M | 1.85M | 5.47M | 48K | 473K | 0 | 0 |
| Days Sales Outstanding | 49.47 | 53.67 | 50.16 | 39.35 | 31.81 | 91.47 | 449.23 | 180.03 | - | - |
| Inventory | 11.08M | 15.42M | 15.23M | 911K | 557K | 550K | 1.24M | 380K | 0 | 0 |
| Days Inventory Outstanding | 107.19 | 151.25 | 356.39 | 31.43 | 29.32 | 76.53 | 1.59K | 306.18 | - | - |
| Other Current Assets | 0 | 7.46M | 5.49M | 0 | 1.29M | 0 | 0 | 1M | 0 | 0 |
| Total Non-Current Assets | 60.49M | 31.53M | 35.1M | 4.9M | 5.03M | 3.86M | 1.62M | 2.06M | 825K | 151K |
| Property, Plant & Equipment | 1.4M | 636K | 209K | 150K | 260K | 219K | 1M | 1.28M | 773K | 119K |
| Fixed Asset Turnover | 135.08x | 125.71x | 186.66x | 210.95x | 81.73x | 99.69x | 0.04x | 0.75x | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 44.28M | 30.88M | 34.88M | 4.74M | 4.75M | 3.62M | 575K | 725K | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 64K | 19K | 12K | 12K | 12K | 21K | 40K | 61K | 52K | 32K |
| Total Assets | 157.27M | 92.11M | 76.12M | 31.74M | 25.03M | 27.46M | 26.32M | 17.07M | 28.33M | 13.44M |
| Asset Turnover | 1.22x | 0.87x | 0.51x | 1.00x | 0.85x | 0.79x | 0.00x | 0.06x | - | - |
| Asset Growth % | 101.67% | 21.01% | 139.83% | 26.81% | -8.87% | 4.35% | 54.16% | -39.73% | 110.72% | - |
| Total Current Liabilities | 54.09M | 38.49M | 19.95M | 16.24M | 6.46M | 4.56M | 3.79M | 1.96M | 2.02M | 793K |
| Accounts Payable | 16.5M | 10.98M | 4.17M | 1.85M | 1.77M | 1.77M | 2.34M | 575K | 1.42M | 539K |
| Days Payables Outstanding | 116.11 | 107.67 | 97.5 | 63.75 | 92.97 | 246.86 | 2.99K | 463.3 | 8.23K | 15.13K |
| Short-Term Debt | 11.84M | 8.79M | 76K | 5.38M | 1.03M | 1.42M | 280K | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -133K | 0 | 0 |
| Other Current Liabilities | 5M | 0 | 15.66M | 0 | 0 | 0 | 0 | 133K | 0 | 0 |
| Current Ratio | 1.79x | 1.57x | 2.06x | 1.65x | 3.10x | 5.18x | 6.51x | 7.65x | 13.59x | 16.76x |
| Quick Ratio | 1.58x | 1.17x | 1.29x | 1.60x | 3.01x | 5.06x | 6.18x | 7.45x | 13.59x | 16.76x |
| Cash Conversion Cycle | 40.55 | 97.26 | 309.05 | 7.02 | -31.84 | -78.86 | -957.17 | 22.91 | - | - |
| Total Non-Current Liabilities | 16.25M | 27.47M | 31.75M | 22K | 5.49M | 5.28M | 6.86M | 4.56M | 1.42M | 520K |
| Long-Term Debt | 11.23M | 21.77M | 29.81M | 0 | 5.38M | 5.26M | 6.76M | 4.54M | 0 | 0 |
| Capital Lease Obligations | 2.1M | 460K | 107K | 22K | 107K | 15K | 99K | 19K | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 4.01M | 3.48M | 1.83M | 0 | 0 | 0 | 0 | 0 | 0 | 520K |
| Total Liabilities | 70.35M | 65.96M | 51.7M | 16.26M | 11.95M | 9.84M | 10.66M | 6.52M | 2.02M | 1.31M |
| Total Debt | 24.09M | 31.02M | 29.99M | 5.4M | 6.52M | 6.7M | 7.14M | 4.56M | 0 | 0 |
| Net Debt | -31.54M | 5.08M | 15.06M | -15.99M | -9.78M | -7.71M | -14.15M | -7.51M | -26.73M | -13.16M |
| Debt / Equity | 0.28x | 1.19x | 1.23x | 0.35x | 0.50x | 0.38x | 0.46x | 0.43x | - | - |
| Debt / EBITDA | 0.53x | 7.54x | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | -0.69x | 1.23x | - | - | - | - | - | - | - | - |
| Interest Coverage | 16.42x | 0.05x | -0.90x | -0.65x | -9.45x | -1.88x | -30.50x | - | - | - |
| Total Equity | 86.92M | 26.15M | 24.43M | 15.48M | 13.08M | 17.63M | 15.66M | 10.55M | 26.3M | 12.13M |
| Equity Growth % | 402.57% | 7.07% | 57.83% | 18.34% | -25.82% | 12.56% | 48.46% | -59.89% | 116.84% | - |
| Book Value per Share | 2.61 | 0.97 | 0.94 | 0.60 | 0.52 | 0.70 | 0.75 | 0.59 | 4.10 | 0.69 |
| Total Shareholders' Equity | 86.92M | 26.15M | 24.43M | 15.48M | 13.08M | 17.63M | 15.66M | 10.55M | 26.3M | 12.13M |
| Common Stock | 29K | 27K | 27K | 26K | 25K | 25K | 24K | 18K | 18K | 6K |
| Retained Earnings | -64.11M | -112.49M | -107.89M | -104.07M | -103.13M | -94.11M | -92.16M | -64.19M | -45.87M | -8.64M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -19M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying ETON stock.
As of 2025, Eton Pharmaceuticals, Inc. (ETON) had total assets of $92.1M including $60.6M in current assets.
Eton Pharmaceuticals, Inc. (ETON) carries total debt of $31.0M, offset by $25.9M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Eton Pharmaceuticals, Inc. (ETON) has total shareholders' equity (book value) of $26.2M ($0.97 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Eton Pharmaceuticals, Inc. (ETON) reported a current ratio of 1.57x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Thin margins and leverage
Metrics are mathematically derived from official filings.
Balance Sheet Strengthening From Deficit Base
According to reported quarterly figures, ETON's total assets expanded from $31.8M in 2024Q2 to $157.3M in 2026Q3, while equity rose from $13.5M to $86.9M, suggesting the balance sheet is strengthening materially from a small base.
The expansion appears driven by a combination of revenue-generating growth and capital raised or retained, with the accumulated deficit narrowing from roughly -$107.9M to -$64.1M over the same period. The improvement in equity points to real earnings contribution rather than balance sheet engineering alone, though the deficit remains large. Investors should monitor whether retained earnings continue to move toward positive territory, as that would confirm the trajectory is durable.
Leverage Volatile Despite Lower Current Debt
Based on ETON's reported figures, total debt stood at $24.1M in 2026Q3 against $29.0M a quarter earlier, with debt-to-equity fluctuating between 0.14 and 1.28 across the ten reported quarters.
The swings in debt-to-equity appear driven more by equity movements than by a clear deleveraging program, suggesting leverage management is opportunistic rather than structural. Total debt of $24.1M remains meaningful relative to recent quarterly operating cash flow, so debt service capacity depends on sustaining the recent cash inflows. Refinancing terms and maturity schedules are not disclosed in the provided data and warrant further investigation.
Cash Buffer Rebuilt by Recent Inflows
As reported in financial statements, ETON's cash position rose to $55.6M in 2026Q3 from $19.7M in 2026Q1, with the current ratio at 1.79, indicating a liquidity buffer that has improved meaningfully within two quarters.
The current ratio of 1.79 suggests short-term obligations are covered, though the margin of safety is modest relative to total liabilities of $70.3M. The jump in cash appears linked to the strong third-quarter operating inflow, which may not be fully recurring. Investors should monitor whether cash holds above the $50M level in subsequent quarters without reliance on new financing.
Asset Base Shifting Toward Intangibles
Based on EDBL's reported figures, goodwill of $44.3M and net PP&E of only $1.4M suggest ETON's asset base is predominantly intangible and asset-light, with goodwill representing a material share of total assets.
The low PP&E balance is consistent with an outsourced manufacturing model typical of specialty pharmaceutical firms rather than an owned production footprint. Goodwill at roughly 28% of total assets concentrates impairment risk if acquired product revenues fall short of acquisition assumptions. Management's recognition and testing of this goodwill is not detailed in the provided data and should be reviewed against the revenue trajectory.
Equity Quality Improving Through Earnings
According to recent reported figures, ETON's equity grew to $86.9M in 2026Q3 while the accumulated deficit narrowed by about $43.8M since 2024Q2, indicating that earnings rather than dilution appear to be driving the equity build.
The growth in equity relative to the reduction in the deficit suggests recent profitability is contributing to book value, though the trailing ROE of -18.2% indicates the cumulative record is still negative. Share count changes and stock-based compensation are not detailed in the provided data, so the extent of dilution cannot be assessed here. Investors should monitor whether future equity growth continues to come from retained earnings rather than new share issuance.
Quarterly Strength May Mask Fragile Profitability
The strongest bear case is that ETON's recent quarterly cash and earnings strength reflects launch timing and working capital release, while the trailing net margin of -5.8% and ROE of -18.2% show durable profitability has not yet been established.
The sharp swings in quarterly operating cash flow and working capital suggest that the recent balance sheet improvement may partly reflect timing rather than recurring cash generation. Goodwill and the debt load amplify downside if revenue growth decelerates after launch-driven demand normalizes. Investors should treat the strengthened cash position as provisional until several consecutive quarters confirm sustainable conversion of revenue into cash.